Development of Stabilimax NZ From Biomechanical Principles

Area of Science:

• Biomechanical Engineering
• Spinal Surgery
• Orthopedics

Background:

• Spinal degeneration and injury are traditionally treated with spinal fusion to limit motion, but complications like adjacent-level syndrome necessitate alternative solutions.
• The neutral zone hypothesis suggests that spinal stabilization, rather than fusion, can reduce pain and improve outcomes.
• Existing treatments often involve restrictive spinal fusion, highlighting the need for motion-preserving alternatives.

Purpose of the Study:

• To develop and evaluate a novel spinal stabilization device, the Stabilimax NZ, as an alternative to spinal fusion.
• To test the hypothesis that spinal stabilization can reduce symptoms without excessive motion restriction.
• To address the limitations of current spinal fusion techniques and their associated complications.

Main Methods:

• Biomechanical experiments were conducted to define performance requirements for the novel device.
• The Stabilimax NZ was designed based on these requirements to stabilize the spine while preserving range of motion.
• Extensive testing of 70 bilateral assemblies of the Stabilimax NZ evaluated biomechanical, static, fatigue, wear, and histological parameters.

Main Results:

• The Stabilimax NZ device successfully decreased the neutral zone in destabilized spines.
• The device maintained a substantial range of motion, unlike fusion procedures.
• All tested assemblies met rigorous biomechanical, static, fatigue, wear, and histological requirements.

Conclusions:

• The Stabilimax NZ device has been systematically designed and tested, meeting all requirements for clinical investigation.
• The device offers a promising alternative for treating spinal degeneration by stabilizing the spine while preserving motion.
• Investigational Device Exemption trial approval has been obtained from the FDA to clinically evaluate the Stabilimax NZ's efficacy.